Compositions comprising 3-hexen-1-ol are described herein, as well as odor-imparting formulations comprising same and articles-of-manufacturing comprising such compositions or odor-imparting formulations. The compositions comprise trans-3-hexen-1-ol in a range of from 67% to 82% by weight and cis-3-hexen-1-ol in a range of from 18% to 33% by weight, wherein a total concentration of trans-3-hexen-1-ol and cis-3-hexen-1-ol is at least 97% by weight. Further described herein is a process for preparing a composition comprising 3-hexen-1-ol, the process comprising: contacting 1-pentene with a formaldehyde in the presence of a Lewis acid to thereby obtain a crude mixture comprising 3-hexen-1-ol; and contacting the mixture comprising 3-hexen-1-ol with a base.

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease). ##STR00001##

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

##STR00001##

Provided is a compound of Formula (I):

##STR00001## wherein the variable groups are defined herein.

Provided is a compound of Formula (I):

##STR00001## wherein the variable groups are defined herein.

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

The invention relates to the use of a CXCR2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN).